

ГЕНОМНЫЙ ПОЛИМОРФИЗМ *HELICOBACTER PYLORI*

GENOTYPES OF *HELICOBACTER PYLORI*

10.15789/2220-7619-GPO-1744

ГЕНОМНЫЙ ПОЛИМОРФИЗМ КЛИНИЧЕСКИХ ИЗОЛЯТОВ

HELICOBACTER PYLORI В САНКТ-ПЕТЕРБУРГЕ, РОССИЯ

Сварваль А.В.,

Старкова Д.А.,

Ферман Р.С.,

Нарвская О.В.

ФБУН НИИ эпидемиологии и микробиологии имени Пастера

GENETIC POLYMORPHISMS OF *HELICOBACTER PYLORI* CLINICAL

ISOLATES IN SAINT PETERSBURG, RUSSIA

Svarval F.,

Starkova D.,

Ferman R.,

Narvskaya O.

St. Petersburg Pasteur Institute, St. Petersburg, Russia

Резюме.

Введение: *Helicobacter pylori* - основной возбудитель гастродуоденальных заболеваний человека. Несмотря на то, что Российская Федерация относится к числу стран с высоким уровнем распространенности *H. pylori*-инфекции (60-90%), в настоящее время довольно ограниченное количество исследований посвящено генетическому разнообразию *H. pylori* в России.

Цель: На основании оценки генов вирулентности *cagA*, *oipA* и *vacA*, целью настоящего исследования явилось изучение геномного полиморфизма клинических изолятов *H. pylori*, полученных от различных групп больных на территории Санкт-Петербурга, Россия.

Материалы и методы: Изучены 61 штамм *H. pylori*, выделенных от пациентов с хроническим гастритом (ХГ), язвой двенадцатиперстной кишки (ЯДК) и раком желудка (РЖ). Стандартный метод ПЦР использовали для детекции генов *cagA*, *oipA* и аллельных вариантов гена *vacA* (s, m, i).

Результаты: Установлена генетическая неоднородность 61 штамма *H. pylori* (HGDI 0.88): 41 (67%) штаммов являлись *cagA*-позитивными, 38 (62%) – *oipA*-позитивными. Доли *cagA*+ штаммов различались у пациентов с ХГ (56,7%) и ЯДК (80,9%) ($p=0,06$). Ген *vacA* в различных s, m, i - аллельных вариантах выявлен у всех штаммов.

Доля штаммов аллельного варианта *vacA* s1 значительно доминировала у пациентов с ЯДК (95,2%), против ХГ (64,9%) ($p=0,01$). Аллели *vacA* m1 и i1 у штаммов от пациентов с ХГ и ЯДК были обнаружены почти в равных пропорциях: 45,9% и 42,8% для аллеля m1, 45,9% и 47,6% для аллеля i1, соответственно. Семь штаммов (11,5%) имели смешанные s, m и i генотипы.

Все штаммы аллеля *vacA* s2 являлись *cagA*-негативными и несли аллель m2.

Штаммы *oipA*+ практически в равных долях были обнаружены у больных ХГ (62,2%) и ЯДК (57,1%), $p=0,71$. Все три штамма от пациентов с РЖ являлись

cagA- и *oipA*- позитивными и несли аллели *vacA* s1/m1/i1. Анализ результатов

генотипирования позволил выявить 17 вариантов профилей

(комбинированных генотипов). Наиболее распространенный

комбинированный генотип *cagA*+/*oipA*+/*vacA*s1/m1/i1 включал 18 (29,5%)

штаммов *H. pylori*. **Выводы:** В результате анализа геномного полиморфизма клинических изолятов *H. pylori*, выделенных от больных хеликобактериозом, были выявлены доминирующие генотипы популяции *H. pylori* в Санкт-Петербурге, Россия. Установлена связь генотипа *vacAs1* возбудителя с клиническими проявлениями *H. pylori*-инфекции.

Ключевые слова: *Helicobacter pylori*, ген *cagA*, ген *vacA*, ген *oipA*, гастрит, язва двенадцатиперстной кишки, рак желудка, гены вирулентности, геномный полиморфизм

Abstract.

Introduction: *Helicobacter pylori* was proved to be the principal causative agent of gastroduodenal disorders in human. Although Russian Federation is among the countries with a high prevalence of *H. pylori* infection (60-90%), there is currently a very limited number of studies evaluating *H. pylori* genotypes in Russia. **Objective:** Based on the assessment of virulence-associated *cagA*, *oipA*, and *vacA* genes, we aimed to determine *H. pylori* genotypes associated with the clinical outcomes in patients with *H. pylori* infection in St. Petersburg, North-West Russia. **Methodology:** Using PCR for the detection of *cagA*, *oipA*, and *vacA* s-, m-, i- allelic variants, we analyzed 61 *H. pylori* isolates isolated and cultured from biopsies collected during endoscopy of patients with chronic gastritis (G), duodenal ulcer (DU), and gastric cancer (GC). **Results:** The genetic diversity of *H. pylori* clinical isolates has been revealed (HGDI 0.88): 41 (67%) of 61 *H. pylori* isolates were *cagA*-positive, 38 (62%) - *oipA*-positive. The proportions of *cagA*+ isolates differed in patients with G (56.7%) and DU (80.9%), ($p=0.06$). The s, m, and i allelic variants of the *vacA* gene were detected in all strains, although the *vacA* s1 allele was significantly dominant in patients with DU (95.2%) rather than with G (64.9%), ($p=0.01$). The *vacA* alleles m1 and i1 in the isolates from patients with G and DU were found in almost equal proportions: 45.9% and 42.8% for m1 allele, 45.9% and 47.6% for i1 allele, respectively. Seven isolates (11.5%) were

positive for different mixed combinations of *vacA* alleles s, m, and i. Noteworthy, all *vacA* s2 strains were *cagA*-negative and had the m2 allele. OipA+ strains were found in almost equal proportions in patients with G (62.2%) and DU (57.1%), $p=0.71$. All three *cagA*- and oipA- positive isolates from patients with GC carried *vacA* s1/m1/i1 alleles. Different combinations of virulence-associated determinants constituted 17 genetic profiles. The most common combined genotype *cagA*+/*oipA*+/*vacAs*1/m1/i1 comprised 18 (29.5%) *H. pylori* isolates. **Conclusion:** We have determined predominant genotypes in the *H. pylori* population in North-West Russia. The significant association between *vacAs*1 genotype of the pathogen and clinical manifestations of *H. pylori* infection has been established in our study.

Keywords: *Helicobacter pylori*, *cagA* gene, *vacA* gene, *oipA* gene, gastritis, duodenal ulcer, gastric cancer, virulence determinants, genomic polymorphism

1 **INTRODUCTION**

2 *Helicobacter pylori*, a microaerophilic gram-negative spiral-shaped
3 bacteria, infects approximately 4.4 billion humans worldwide. Although most *H.*
4 *pylori*-positive individuals remain asymptomatic, the infection may result in the
5 development of gastritis, ulcer disease, gastric adenocarcinoma, and mucosa-
6 associated lymphoid tissue lymphoma [1].

7 The severity of gastroduodenal lesions in infected individuals depends on
8 the environmental factors, host genetics, and the expression of a large variety of
9 virulence factors in *H. pylori* strains that play a key role in the development of the
10 infection. Presently, the most intensively studied are the vacuolating cytotoxin
11 (VacA), cytotoxin-associated antigen A (CagA), and outer inflammatory protein
12 (OipA) encoded by *vacA*, *cagA*, and *oipA* genes, respectively [1, 2].

13 The *vacA* gene found in the genome of all *H. pylori* strains encodes a
14 cytotoxin (~140 kDa), inducing the vacuolization of gastric epithelial cells through
15 the formation of anion-selective pores in the cytoplasmic membrane. The genetic
16 diversity of *H. pylori* strains is associated with *vacA* allelic variants s (alleles
17 s1/s2), i (alleles i1/i2/i3), and m (alleles m1/m2) due to the mosaic structure of the
18 *vacA* gene [3, 4]. The product of *vacA* in *H. pylori* s1/m1/i1 genotype strains is
19 considered the most cytotoxic and associated with ulcer disease and gastric
20 carcinoma compared with strains of other genotypes [5].

21 The primary determinant of *H. pylori* virulence is the *cag* pathogenicity
22 island (*cagPAI*) believed to contribute to clinical outcomes, which seems
23 controversial. For instance, a strong association between *cagA* status and severity
24 of the disease was reported in the developed European countries [6]. In Russia and
25 most Asian countries, such contribution was not proved [7, 8]. The *cagPAI* genes
26 encode for the type IV secretion system proteins that transport the immunogenic
27 CagA protein to the epithelial cells of the gastric mucosa. Further phosphorylation
28 of CagA by host protein kinases results in the morphological changes in epithelial
29 cells that stimulate ulceration, atrophy, and stomach cancer [9]. The marker of

30 the *cagPAI* is the *cagA* gene, which is present in the genome of 25-99% of *H.*
31 *pylori* strains depending on their geographical origin [6, 7, 8].

32 The outer membrane protein OipA, a member of the HOP protein family
33 (*Helicobacter outer proteins*), is encoded by the *oipA* gene, which can be
34 functionally active ("on") or inactive ("off") due to regulation by the repeated CT
35 motif in the nucleotide sequence. OipA protein provides adhesion of *H. pylori* to
36 gastric epithelial cells and is associated with interleukin-8 induction and neutrophil
37 infiltration of the gastric mucosa in inflammation and duodenal ulcer [10].

38 Although Russia belongs to countries with a high prevalence of *H. pylori*
39 infection (70-90% depending on the region), currently there is a very limited
40 number of studies evaluated *H. pylori* genotypes in Russia. Based on the
41 assessment of virulence-associated *cagA*, *oipA*, and *vacA* genes, we aimed to
42 determine *H. pylori* genotypes associated with the clinical outcomes in patients
43 with *H. pylori* infection in St. Petersburg, North-West Russia.

44

45 **METHODS**

46

47 **Bacterial strains, culture conditions, and identification**

48 A total of 240 patients with a confirmed diagnosis of *H. pylori* infection
49 from three different hospitals (in St. Petersburg) between 2014 and 2019 were
50 recruited. From this cohort, only 122 biopsies from both the corpus and antral
51 mucosa taken during endoscopy from 61 patients were available. The patients were
52 28 men (45.9%) and 33 women (54.1%). The median age was 44 years (range 17-
53 88 years). Regarding endoscopic findings and histological routine results, 61
54 patients were classified into chronic gastritis (n=37, 60.7%), duodenal ulcer (n=21,
55 34.4%) and gastric cancer (n=3, 4.9%). The retrospective study was approved by
56 the Independent Ethics Committee of the St. Petersburg Pasteur Institute, Russia
57 (protocol № 50/04-2019, 22.06.2020).

58 Endoscopic biopsy specimens were homogenized and used for the culture.
59 The *H. pylori* culture was carried out at the St. Petersburg Pasteur Institute (Russia)

60 on a medium containing Columbia agar base with the addition of 5-7%
61 defibrinated horse blood and 1% IsoVitalex solution at 37°C under microaerophilic
62 conditions (oxygen content ~ 5%) using anaerostats of the GasPac 100 system.
63 Visible growth of bacteria was observed after 4-7 days. For primary identification,
64 Gram-stained culture smears were studied by microscopy. The urease, catalase,
65 and oxidase biochemical tests were used for species identification. The strains
66 were identified as *H. pylori* if all tests were positive. Strain *H. pylori* NCTC 12823
67 was used as a reference.

68

69 **DNA extraction and polymerase chain reaction (PCR) assays**

70 Isolation of chromosomal DNA *H. pylori* was performed using a set of
71 "Helicopol II" produced by NPF "Litech" (Moscow).

72 The PCR for the detection of *cagA*, *oipA*, and *vacA* genes in the DNA
73 samples was performed in the Bio-Rad C1000 Thermal Cycler (USA). The
74 nucleotide sequences of the primers, the annealing temperatures, and the lengths of
75 amplification products are shown in Table 1.

76 PCR protocol: 95°C - 3 min.; 35 cycles: 94°C - 35 sec., annealing
77 temperature - 35 sec., 72°C - 45 sec.; 72°C - 5 min. PCR products were separated
78 in a 2% agarose gel stained with ethidium bromide. The length of amplification
79 products was determined using molecular weight markers of 50 bp and 100 bp
80 DNA Ladder (LLC Interlabservis, Moscow). The results were visualized using the
81 GelDoc gel documentation system (BioRad, USA).

82

83 **Statistical analysis**

84 The statistical analysis of group comparison was performed using SPSS for
85 Windows statistical software (version 12; StatSoft Inc., Chicago, IL, USA) and the
86 OpenEpi (a Web-based Epidemiologic and Statistical Calculator for Public Health
87 (www.OpenEpi.com)) for two-by-two tables to calculate the odds ratio (OR) and
88 95% confidence interval (CI) and the Fisher exact test (one-tailed). A p-value
89 <0.05 was considered statistically significant.

90 To quantitatively evaluate the variability of *cagA*, *oipA*, and *vacA* genes, the
91 Hunter–Gaston discriminatory index was calculated (HGDI) using an algorithm
92 from http://insilico.ehu.es/mini_tools/discriminatory_power/index.php.

93 RESULTS

94 The culture of biopsies on a selective nutrient medium at 37°C in
95 microaerophilic conditions after 4-7 days resulted in the visible growth of typically
96 small (about 1 mm diameter), round, smooth, transparent, moist colonies
97 containing Gram-negative curved/S-shaped rods. Positive results of biochemical
98 tests (the ability to produce catalase, oxidase, and urease) allowed us to identify 61
99 bacterial isolates as *H. pylori* species.

100 The PCR-based examination of DNA samples revealed the genetic diversity
101 of *H. pylori* clinical isolates in terms of the presence of virulence-associated genes
102 *cagA*, *oipA*, and the distribution of *vacA* allelic variants (HGDI 0.88) (Table 2).
103 The 41 (67%) of the 61 strains were *cagA*-positive, 38 (62%) - *oipA*-positive;
104 the *vacA* gene in various allelic variants was detected in all strains. The s1 (77%),
105 m2 (49%), and i1 (49%) alleles were the most frequent in polymorphic s, m, and i
106 regions of the *vacA* gene. Seven isolates (11.5%) were positive for different mixed
107 combinations of *vacA* alleles s, m, and i (Table 4). Such cases may indicate the
108 presence of multiple strains in the human body.

109 Allelic variants of three regions of the *vacA* gene were grouped into five
110 genotypes, among them *vacA* s1/m1/i1 was dominant (41%). The *vacA* s1/m2/i2
111 and *vacA* s2/m2/i2 genotypes included 10 and 12 strains (16% and 20%),
112 respectively. Noteworthy, a rare s2/m1 genotype was not found in our study.

113 To assess the association of pathogen's virulence determinants with the
114 severity of gastroduodenal lesions due to *H. pylori* infection, we analyzed the
115 distribution of *cagA*, *oipA*, and *vacA* genes in *H. pylori* clinical isolates from
116 patients diagnosed with chronic gastritis (G), duodenal ulcer (DU) and gastric
117 cancer (GC) (Table 2).

118 The proportions of *cagA*+ *H. pylori* strains differed depending on the clinical
119 manifestations. In patients with G it was 56.7%, while in patients with

120 DU reached 80.9%, however, the difference was not statistically
121 significant [p=0.06; OR 3.24 (0.91; 11.52)].

122 The distribution of strains bearing *vacA* s1 allele significantly differed in
123 patients with G (64.9%) and DU (95.2%): [p=0.01; OR 10.833 (1.30; 90.14)].

124 The *vacA* alleles m1 and i1 in the isolates from patients with G and DU were found
125 in almost equal proportions: p=0.82 (for allele m1) and p=0.90 (for allele i1).

126 Also, no statistical difference between the *oipA* status and severity of the
127 disease was detected: the proportions of *oipA*+ strains in patients with G (62.2%)
128 and DU (57.1%) were almost equal (p=0.71).

129 All isolates from patients with GC were *cagA*-, *oipA*- positive, and
130 carried *vacA* s1/m1/i1 alleles (Table 2).

131 Further analysis of the *vacA*- and *cagA*-associated polymorphism in *H.*
132 *pylori* clinical isolates revealed a relationship between the *cagA*+ status and the
133 allelic variant s1 of the *vacA* gene: among 41 *cagA*-positive strains 39 (95.1%)
134 possessed the *vacA* s1 allele (two *cagA*+ strains had multiple genotype s1s2), while
135 none of the *vacA* s2 bearing strains carried *cagA* gene. Noteworthy, all *vacA* s2
136 strains had the m2 allele (Table 3). Only 24 (58%) of *cagA*-positive strains were
137 *vacA* m1. The majority (88%) of the *vacA* s1/m1/i1 allelic profile strains were
138 *cagA*-positive. The majority of *oipA*-positive isolates (87%) were carriers of the
139 *cagA* gene.

140 The proportion of *cagA*+/*vacA*s1 genotype strains in patients with G reached
141 51%, compared to larger proportions in patients with DU (81%) and GC (100%).
142 Only one of the 21 isolates from patients with DU had the *cagA*-/*vacA*s2 genotype.

143 Different combinations of *cagA/oipA/vacA* alleles in 61 clinical *H. pylori*
144 isolates were grouped in 17 profiles, five of which represented multiple genotypes
145 (Table 4). The most common variant was *cagA*+/*oipA*+/*vacA*s1/m1/i1 which
146 comprised 18 (30%) of the strains isolated from patients with G, DU, and GC. The
147 remaining genotypes were represented by groups, including 1 to 6 strains.

148

149 DISCUSSION

150 The populations of *H. pylori* appear heterogenic in different countries with
151 variable ethnic, socioeconomic, and environmental characteristics. The
152 polymorphisms in *cagA* and *vacA* genes associated with virulence are widely
153 exploited for the genotyping of *H. pylori* strains. The presence of the *cagA* gene (a
154 marker of the pathogenicity island, *cagPAI*) varies among *H. pylori* strains of
155 different geographical origin: ~ 80-99% in East Asian countries [8, 14], Southeast
156 and South Asia [15,16,17], South Africa [18]; ~ 50-70% in countries of Western
157 Europe [6,19,20,21]; ~ 50% and lower in the countries of the Middle East [22,23].
158 According to the studies conducted in the Russian Federation, the presence of
159 *cagA*-positive *H. pylori* strains varies in different regions: 80-90% in Moscow
160 (Central region) [7] and Yekaterinburg (Ural Federal District) [24], 70-80% in
161 Rostov-on-Don, Astrakhan (Southern Federal District) [41], 30-60% in Eastern
162 Siberia [26], <50% in Kazan (Volga Federal District) [27].

163 In this study, we detected about 67% of *cagA*-positive *H. pylori* strains
164 among patients from St. Petersburg, which is consistent with data from Europe. In
165 particular, in Finland, the proportion of *cagA*+ *H. pylori* strains reached 66%. The
166 observed similarities may be partly explained by the territorial neighborhood and
167 close communication between St. Petersburg region, Russia, and Finland.

168 It is generally accepted that CagA-negative *H. pylori* strains are less virulent
169 than CagA-positive strains causing severe gastrointestinal lesions in humans. The
170 *cagA*-positive strains are reported in 80-100% of patients with DU and G in
171 Europe. In our study, the *cagA* gene was observed in *H. pylori* isolates from
172 patients with DU (81%) and GC (100%), which is consistent with the previously
173 published data [6,19,20] In Asia, almost all strains of *H. pylori* carry the *cagA*
174 gene, regardless of the infection severity [8], thus emphasizing the role of the
175 CagA protein as a pathogen's virulence factor.

176 The *vacA* gene is known to be present in the genome of all *H. pylori* strains.
177 However, the different levels of cytotoxic activity of VacA protein are were
178 associated with the diversity of allelic variants in the s-, m-, and i-regions of the
179 *vacA* gene [4,5].

180 We have established an association between the *vacA* s1 allele and DU since
181 only one of the 21 *H. pylori* strains possessed an alternative *vacA* s2. Interestingly,
182 that *vacA* s2 allele was predominant in *H. pylori* isolates from patients with G
183 (~92%). No similar association was found in the m-variants of the *vacA* gene: the
184 m1 and m2 alleles were distributed almost equally among clinical isolates from
185 patients with G (45.9% and 48.6%, respectively) and DU (42.8% and 57.1%,
186 respectively). In contrast to the widespread opinion on the leading role of the *H.*
187 *pylori vacA* s1/m1 genotype in the development of a duodenal ulcer, our data did
188 not confirm such association: we observed almost similar proportions of the s1/m1
189 and s1/m2 genotypes in patients with DU (42.8% and 52.4%, respectively).
190 However, the s1/m1 genotype was detected in *H. pylori* isolates from patients with
191 GC (though the number of such isolates was limited to three in our study), which is
192 consistent with the reports from the Netherlands, Portugal [28,29]. These data
193 suggest a variety of *H. pylori* virulence determinants associated with the severity of
194 lesions during infection of the gastrointestinal tract.

195 Polymorphism of the intermediate i region of the *vacA* gene is determined
196 by alternative alleles i1/i2. According to published data, the *vacA* i1 allele appears
197 more informative than the s1/m1 allele and can be considered as an independent
198 "marker" of gastric cancer [14].

199 We found that all *vacA* s1/m1 and *vacA* s2/m2 *H. pylori* isolates carried the
200 i1 (*vacA* s1/m1/i1) and i2 (*vacA* s2/m2/i2) alleles, respectively. On the contrary,
201 *vacA* s1/m2 genotype isolates appeared heterogeneous in the i-region (*vacA*
202 s1/m2/i1 and *vacA* s1/m2/i2), which is in line with other reports [8, 14]. All *H.*
203 *pylori* isolates from patients with gastric cancer (n=3) were carriers of the *vacA* i1
204 allele combined with s1/m1. However, there was no correlation of *vacA* i1
205 genotype with other forms of *H. pylori* infection: 45.9% *vacA* i1 isolates from
206 patients with G versus 47.6% from patients with DU. Thus, a large-scale
207 assessment of the *vacA* i1 allele as a putative marker of predisposition to gastric
208 cancer is necessary.

209 Based on the *vacA* genotyping, our results suggest the coexistence of
210 multiple genetically different *H. pylori* strains in various gastric sites resulting
211 from the mixt infection in a considerable number of patients (7/61, 11.5%).

212 An analysis of the *H. pylori cagA* and *vacA* combined genotypes
213 demonstrated, firstly, the association of the *cagPAI* region with the *vacA* s1 allele
214 and the absence of *cagPAI* in *vacA* s2 strains; secondly, the association of DU with
215 the *vacA* s1 genotype. The *vacAs2* strains were unique for patients with G. These
216 data support the generally accepted opinion that *vacA* s1 strains increase the risk of
217 developing DU and GC, while *vacA* s2 strains are less virulent and rarely
218 associated with the progress of *H. pylori* infection. The *vacAi1* and *vacAm1*
219 genotypes of *H. pylori* isolates were not associated with DU.

220 It is believed that the functionally active *oipA* gene is associated with the
221 presence of the *cagA* gene, which, in turn, is associated with the *H. pylori vacA* s-
222 region [13,30]. However, their relationships remain unclear, taking into account
223 the mutual remoteness of the *oipA*, *cagA*, and *vacA* genes on the bacterial
224 chromosome.

225 In our study, a functionally active *oipA*⁺ gene was found in 62% of *H. pylori*
226 isolates, while several studies reported the presence of the *oipA* gene in 90-100%
227 strains [10,30]. Most *oipA*-positive isolates (80%) carried the *cagA* gene. We did
228 not find links between the presence of *oipA* gene and *H. pylori*-mediated diseases:
229 the frequency of *oipA*⁺ strains in patients with G and DU was similar (60%). At
230 the same time, the *oipA*⁺ isolates have predominated in patients with GC (100%),
231 though the low number of gastric cancer cases in our study did not allow us to
232 confirm an association.

233 The present study revealed the dominant combined genotype
234 *cagA*⁺/*oipA*⁺/*s1*/*m1*/*i1* in *H. pylori* clinical isolates (30%). Our results inspire to
235 search for reliable genetic markers associated with various clinical manifestations
236 of *H. pylori* infection.

237 In conclusion, the PCR-based analysis of virulence determinants in clinical
238 isolates revealed heterogeneity and the predominant genotypes in the *H. pylori*

239 population in St. Petersburg, Russia. Although Russia belongs to countries with a
240 high prevalence of *H. pylori* infection, a relatively low proportion of the *cagA*-
241 bearing isolates were detected, and they were not significantly associated with
242 duodenal ulcer. The significant association between the *vacAs1* genotype of the
243 pathogen and clinical manifestations of *H. pylori* infection has been established.
244 Despite the limitations in the number of specimens, this finding may serve as a
245 potential predictor for the *H. pylori* disease progression. A large-scale assessment
246 is a demand to reveal the actual risk in developing gastroduodenal diseases due to
247 *H. pylori* infection in Russia. In general, our study gained new insights into the *H.*
248 *pylori* genetic structure in St. Petersburg, thus contributing to Russian and global
249 pathogen population characterizations.

ТАБЛИЦЫ

Table 1. Primers used for PCR detection of *oipA*, *cagA*, and *vacA* genes

Genes	Primers	Sequence of primers	Annealing temperature, °C	Length of the PCR product, bp	Reference
<i>oipA</i>	OipA-F OipA-R	GTTTTTGATGCATGGGATTT GTGCATCTCTTATGGCTTT	53	401	11
<i>cagA</i>	CagA-F CagA-R	GATAACAGGCAAGCTTTTGAGG CTGCAAAAGATTGTTTGGCAGA	56	349	12
<i>vacA</i> s1/s2	VAI-F VAI-R	ATGGAAATACAACAACACAC CTGCTTGAATGCGCCAAAC	53	259/286	3
<i>vacA</i> m1/m2	VAG-F VAG-R	CAATCTGTCCAATCAAGCGAG GCGTCAAAATAATTCCAAGG	52	570/645	13
<i>vacA</i> i1	VacF1 VacA-C1R	GTTGGGATTGGGGGAATGCCG TTAATTTAACGCTGTTTGAAG	52	426	4
<i>vacA</i> i2	VacF1 VacA-C2R	GTTGGGATTGGGGGAATGCCG GATCAACGCTCTGATTTGA	52	432	4

Table 2. Genotypes of *H. pylori* clinical isolates from different patient groups

<i>H. pylori</i> genotype	G, N (%) (n=37)	DU, N (%) (n=21)	GC, N (%) (n=3)	Total, N (%) (n=61)
<i>cagA</i> +	21 (56.7%)	17 (80.9%)	3 (100%)	41 (67.2%)
<i>oipA</i> +	23 (62.2%)	12 (57.1%)	3 (100%)	38 (62.3%)
<i>vacA</i> s1	24 (64.9%)	20 (95.2%)	3 (100%)	47 (77.0%)
<i>vacA</i> s2	11 (29.7%)	1 (4.8%)	-	12 (19.7%)
<i>vacA</i> s1s2	2 (5.4%)	-	-	2 (3.3%)
<i>vacA</i> m1	17 (45.9%)	9 (42.8%)	3 (100%)	29 (47.5%)
<i>vacA</i> m2	18 (48.6%)	12 (57.1%)	-	30 (49.2%)
<i>vacA</i> m1m1	2 (5.4%)	-	-	2 (3.3%)
<i>vacA</i> i1	17 (45.9%)	10 (47.6%)	3 (100%)	30 (49.2%)
<i>vacA</i> i2	17 (45.9%)	7 (33.3%)	-	24 (39.3%)
<i>vacA</i> ili2	3 (8.1%)	4 (19.0%)	-	7 (11.5%)
<i>vacA</i> s1/m1/i1	17 (48.5%)	11 (47.8%)	3 (100%)	31 (50.8%)
<i>vacA</i> s2/m2/i2	11 (31.4%)	1 (4.3%)	-	12 (19.7%)
<i>vacA</i> s1/m2/i2	4 (11.4%)	9 (39.1%)	-	13 (21.3%)
<i>vacA</i> s1/m2/i1	3 (8.5%)	2 (8.6%)	-	5 (8.2%)

<i>vacA</i> s1/m2/i1i2	-	3 (14.3%)	-	3 (4.9%)
<i>vacA</i> s1/m1/i1i2	-	1 (4.8%)	-	1 (1.6%)
<i>vacA</i> s1s2/m1m2/i1i2	1 (2.7%)	-	-	1 (1.6%)
<i>vacA</i> s1s2/m1/i1i2	1 (2.7%)	-	-	1 (1.6%)
<i>vacA</i> s1/m1m2/i1i2	1 (2.7%)	-	-	1 (1.6%)

Table 3. The distribution of *vacA* and *oipA* profiles in *cagA*-positive and *cagA*-negative *H. pylori* clinical isolates

<i>H. pylori</i> genotype	<i>cagA</i> +, N (%) (n=41)	<i>cagA</i> -, N (%) (n=20)	Total, N (%) (n=61)
<i>vacA</i> s1	39 (95.1%)	8 (40.0%)	47 (77.0%)
<i>vacA</i> s2	-	12 (60.0%)	12 (19.6%)
<i>vacA</i> m1	24 (58.5%)	5 (25.0%)	29 (47.5%)
<i>vacA</i> m2	15 (36.6%)	15 (75.0%)	30 (49.2%)
<i>vacA</i> i1	26 (63.4%)	4 (20.0%)	30 (49.2%)
<i>vacA</i> i2	8 (19.5%)	16 (80.0%)	24 (39.3%)
<i>vacA</i> s1/m1/i1	22 (53.6%)	3 (15.0%)	25 (40.9%)
<i>vacA</i> s1/m2/i1	4 (9.7%)	1 (5.0%)	5 (8.2%)
<i>vacA</i> s1/m2/i2	8 (19.5%)	2 (10.0%)	10 (16.4%)
<i>vacA</i> s2/m2/i2	-	12 (60.0%)	12 (19.7%)
<i>oipA</i> +	33 (80.5%)	5 (25.0%)	38 (62.3%)
<i>oipA</i> -	8 (19.5%)	15 (75.0%)	23 (37.7%)
<i>vacA</i> s1s2/m1m2/i1i2	1 (2.4%)	-	1 (1.6%)
<i>vacA</i> s1s2/m1/i1i2	1 (2.4%)	-	1 (1.6%)
<i>vacA</i> s1/m1m2/i1i2	1 (2.4%)	-	1 (1.6%)
<i>vacA</i> s1/m1/i1i2	1 (2.4%)	-	1 (1.6%)
<i>vacA</i> s1/m2/i1i2	3 (7.3%)	-	3 (4.9%)

Table 4. Combined genotypes of *H. pylori* clinical isolates from different patient groups

Combined <i>H. pylori</i> genotypes	G (n=37)	DU (n=21)	GC (n=3)	Total (n=61)
<i>cagA</i> +/ <i>oipA</i> +/ <i>vacAs1</i> /m1/i1	10 (27.0%)	5 (23.8%)	3 (100%)	18 (29.5%)
<i>cagA</i> +/ <i>oipA</i> +/ <i>vacAs1</i> /m2/i2	3 (8.1%)	3 (14.3%)	-	6 (9.8%)
<i>cagA</i> +/ <i>oipA</i> +/ <i>vacAs1</i> /m2/i1	2 (5.4%)	-	-	2 (3.3%)
<i>cagA</i> +/ <i>oipA</i> -/ <i>vacAs1</i> /m1/i1	2 (5.4%)	2 (9.5%)	-	4 (6.5%)
<i>cagA</i> +/ <i>oipA</i> -/ <i>vacAs1</i> /m2/i1	1 (2.7%)	1 (4.8%)	-	2 (3.3%)
<i>cagA</i> +/ <i>oipA</i> -/ <i>vacAs1</i> /m2/i2	-	2 (9.5%)	-	2 (3.3%)
<i>cagA</i> -/ <i>oipA</i> +/ <i>vacAs2</i> /m2/i2	5 (13.5%)	-	-	5 (8.2%)
<i>cagA</i> -/ <i>oipA</i> -/ <i>vacAs1</i> /m1/i1	2 (5.4%)	1 (4.8%)	-	3 (4.9%)
<i>cagA</i> -/ <i>oipA</i> -/ <i>vacAs1</i> /m1/i2	2 (5.4%)	-	-	2 (3.3%)
<i>cagA</i> -/ <i>oipA</i> -/ <i>vacAs1</i> /m2/i2	1 (2.7%)	1 (4.8%)	-	2 (3.3%)
<i>cagA</i> -/ <i>oipA</i> -/ <i>vacAs2</i> /m2/i2	6 (16.2%)	1 (4.8%)	-	7 (11.5%)
<i>cagA</i> -/ <i>oipA</i> -/ <i>vacAs1</i> /m2/i1	-	1 (4.8%)	-	1 (1.6%)
<i>cagA</i> +/ <i>oipA</i> +/ <i>vacAs1s2</i> /m1m2/i1i 2	1 (2.7%)	-	-	1 (1.6%)
<i>cagA</i> +/ <i>oipA</i> +/ <i>vacAs1s2</i> /m1/i1i2	1 (2.7%)	-	-	1 (1.6%)

<i>cagA</i> +/ <i>oipA</i> +/ <i>vacAs1</i> /m1m2/i1i2	1 (2.7%)	-	-	1 (1.6%)
<i>cagA</i> +/ <i>oipA</i> +/ <i>vacAs1</i> /m1/i1i2	-	1 (4.8%)	-	1 (1.6%)
<i>cagA</i> +/ <i>oipA</i> +/ <i>vacAs1</i> /m2/i1i2	-	3 (14.3%)	-	3 (4.9%)

ТИТУЛЬНЫЙ ЛИСТ_МЕТАДААННЫЕ

GENETIC POLYMORPHISMS OF *HELICOBACTER PYLORI* CLINICAL
ISOLATES IN SAINT PETERSBURG, RUSSIA

ГЕНОМНЫЙ ПОЛИМОРФИЗМ КЛИНИЧЕСКИХ ИЗОЛЯТОВ
HELICOBACTER PYLORI В САНКТ-ПЕТЕРБУРГЕ, РОССИЯ

*Corresponding author at: **Daria Starkova^a**, PhD

^a Researcher of Department for Identification of Pathogens / Department of Molecular Epidemiology and Evolutionary Genetics Laboratory of Molecular Epidemiology and Evolutionary Genetics, St. Petersburg Pasteur Institute, St. Petersburg, Russia

197101 Mira str., 14

<https://orcid.org/0000-0003-3199-8689>

e-mail: dariastarkova13@gmail.com Tel: +7921 424 6337; 8-812-233-21-49

Автор для переписки: Старкова Дарья Андреевна¹, к.б.н., старший научный сотрудник лаборатории идентификации патогенов / научный сотрудник лаборатории молекулярной эпидемиологии и эволюционной генетики

¹ Федеральное бюджетное учреждение науки «Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН НИИ эпидемиологии и микробиологии имени Пастера)

ул. Мира 14, Санкт-Петербург, 197101

Информация об авторах:

Alena Svarval^a, PhD,

^a Head of Department for Identification of Pathogens, St. Petersburg Pasteur Institute, St. Petersburg, Russia

ORCID 0000-0001-9340-4132

Алена Владимировна Сварваль¹, к.м.н.

¹ старший научный сотрудник, заведующая лабораторией идентификации патогенов, ФБУН НИИ эпидемиологии и микробиологии имени Пастера

Daria Starkova^a, PhD

^a Researcher of Department for Identification of Pathogens / Department of Molecular Epidemiology and Evolutionary Genetics Laboratory of Molecular Epidemiology and Evolutionary Genetics, St. Petersburg Pasteur Institute, St. Petersburg, Russia

<https://orcid.org/0000-0003-3199-8689>

e-mail: dariastarkova13@gmail.com Тел: +7921 424 6337;

Старкова Дарья Андреевна¹ к.б.н.

¹старший научный сотрудник лаборатории идентификации патогенов / научный сотрудник лаборатории молекулярной эпидемиологии и эволюционной генетики, ФБУН НИИ эпидемиологии и микробиологии имени Пастера

Raisa Ferman^a

^a Researcher of Department for Identification of Pathogens, St. Petersburg Pasteur Institute, St. Petersburg, Russia

ORCID ID 0000-0001-7661-3725

Раиса Семеновна Ферман¹

¹ младший научный сотрудник лаборатории идентификации патогенов, ФБУН НИИ эпидемиологии и микробиологии имени Пастера;

Olga Narvskaya^{a,b} PhD, Professor

^a Researcher of Department of Molecular Epidemiology and Evolutionary Genetics, St. Petersburg Pasteur Institute, St. Petersburg, Russia

^b scientific advisor of St. Petersburg Research Institute of Phthisiopulmonology, St. Petersburg, Russia

ORCID ID 0000-0002-0830-5808

Ольга Викторовна Нарвская^{1,2} д.м.н., профессор

¹ ведущий научный сотрудник лаборатории молекулярной эпидемиологии и эволюционной генетики, ФБУН НИИ эпидемиологии и микробиологии имени Пастера;

² научный консультант ФГБУ «СПб НИИФ» Минздрава России

A. Svarval, D. Starkova, R. Ferman, O. Narvskaya

Сварваль А.В., Старкова Д.А., Ферман Р.С., Нарвская О.В.

ФБУН НИИ эпидемиологии и микробиологии имени Пастера

St. Petersburg Pasteur Institute, St. Petersburg, Russia

Метаданные:

Сокращенное название статьи:

GENETIC POLYMORPHISMS OF *HELICOBACTER PYLORI*

ГЕНОМНЫЙ ПОЛИМОРФИЗМ *HELICOBACTER PYLORI*

Ключевые слова: *Helicobacter pylori*, ген *cagA*, ген *vacA*, ген *oipA*, гастрит, язва двенадцатиперстной кишки, рак желудка, гены вирулентности, геномный полиморфизм

Keywords: *Helicobacter pylori*, *cagA* gene, *vacA* gene, *oipA* gene, gastritis, duodenal ulcer, gastric cancer, virulence determinants, genomic polymorphism

9 страниц текста статьи, 4 таблицы

Оригинальная статья

Дата отправления: 04.06.2020

СПИСОК ЛИТЕРАТУРЫ

Порядковый номер ссылки	Авторы, название публикации и источника, где она опубликована, выходные данные	ФИО, название публикации и источника на английском	URL/DOI
1	de Brito B.B., da Silva F.A.F., Soares A.S, Pereira V.A., Santos M.L.C., Sampaio M.M., Neves P.H.M., de Melo F.F. Pathogenesis and clinical management of Helicobacter pylori gastric infection. World. J. Gastroenterol., 2019, vol.25, no.37, pp. 5578-89.		DOI: 10.3748/wjg.v25.i37.5578
2	Imkamp F., Lauener F.N., Pohl D., Lehours P., Vale F.F., Jehanne Q., Zbinden R., Keller P.M., Wagner K. Rapid characterization of virulence determinants in Helicobacter pylori isolated from non-atrophic gastritis patients by next-generation sequencing. J. Clin. Med., 2019, vol.8, no.7, :1030.		DOI: 10.3390/jcm8071030
3	Atherton J.C., Cao P., Peek R.M.,		DOI: 10.1074/jbc.270.30.17771

	Tummuru M.K., Blaser M.J., Cover T.L. Mosaicism in vacuolating cytotoxin alleles of <i>Helicobacter pylori</i> . Association of specific vacA types with cytotoxin production and peptic ulceration. <i>J. Biol. Chem.</i> , 1995, vol.270, pp.17771–17777.		
4	Rhead J.L., Letley D.P., Mohammadi M., Hussein N., Mohagheghi M.A., Eshagh Hosseini M., Atherton J.C. A new <i>Helicobacter pylori</i> vacuolating cytotoxin determinant, the intermediate region, is associated with gastric cancer. <i>Gastroenter.</i> , 2007, vol.133, no.3, pp.926-36.		DOI: 10.1053/j.gastro.2007.06.056
5	Foegeding N.J., Caston R.R., McClain M.S., Ohi M.D., Cover T.L. An Overview of <i>Helicobacter pylori</i> VacA Toxin Biology. <i>Toxins (Basel)</i> , 2016, vol.8, no.6, e173.		DOI: 10.3390/toxins8060173
6	Kamogawa-Schifter Y., Yamaoka Y., Uchida T., Beer A., Tribl B., Schöniger-Hekele M., Trauner M., Dolak W. Prevalence of <i>Helicobacter</i>		DOI: 10.1371/journal.pone.0197695

	pylori and its CagA subtypes in gastric cancer and duodenal ulcer at an Austrian tertiary referral center over 25 years. PLoS One, 2018, vol.13, no.5, e0197695.		
7	Momynaliev K., Smirnova O., Kudryavtseva L., Govorun V. Helicobacter pylori genotypes in Russia. Eur. J. Clin. Microbiol. Infect. Dis., 2003, vol.22, no.9, pp.573-574.		DOI: 10.1007/s10096-003-0987-2
8	Nguyen L.T., Uchida T., Murakami K., Fujioka T., Moriyama M. Helicobacter pylori virulence and the diversity of gastric cancer in Asia. J. Med. Microbiol., 2008, vol.57, no.12, pp.1445-1453.		DOI: 10.1099/jmm.0.2008/003160-0
9	da Costa D.M., Pereira Edos S., Rabenhorst S.H. What exists beyond cagA and vacA? Helicobacter pylori genes in gastric diseases. World J. Gastroenterol., 2015, vol.21, no.37, pp.10563-10572.		DOI: 10.3748/wjg.v21.i37.10563
10	Braga L.L.B.C., Batista M.H.R., de Azevedo O.G.R., da Silva Costa K.C.,		DOI: 10.1186/s12885-018-5249-x

	Gomes A.D., Rocha G.A., Queiroz D.M.M. OipA "on" status of <i>Helicobacter pylori</i> is associated with gastric cancer in North-Eastern Brazil. <i>BMC Cancer</i> , 2019, vol.19, no.1, pp. 48.		
11	Versalovic J., Koeuth T., Lupski J.R.. Distribution of repetitive DNA sequences in Eubacteria and application to fingerprinting of bacterial genomes. <i>Nucleic Acids Res.</i> , 1991, vol.19, pp.6823–6831.		DOI: 10.1093/nar/19.24.6823
12	Tumurru M.K., Cover T.L., Blaser M.J. Cloning and expression of a high-molecular mass major antigen of <i>Helicobacter pylori</i> : evidence of linkage to cytotoxin production. <i>Infect. Immun.</i> , 1993, vol.61, pp.1799–1809.		
13	Yamaoka Y., Kodama T., Gutierrez O., Kim J.G., Kashima K., Graham D.Y. Relationship between <i>Helicobacter pylori</i> <i>iceA</i> , <i>cagA</i> , and <i>vacA</i> status and clinical outcome:		

	studies in four different countries. J. Clin. Microbiol., 1999, vol.37, pp.2274–2279.		
14	Inagaki T., Nishiumi S., Ito Y., Yamakawa A., Yamazaki Y., Yoshida M., Azuma T. Associations between <i>cagA</i> , <i>vacA</i> , and the clinical outcomes of <i>Helicobacter pylori</i> infections in Okinawa, Japan. Kobe J. Med. Sci., 2017, vol.63, no.2, pp.58-67.		
15	Uchida T., Miftahussurur M., Pittayanon R., Vilaichone R.K., Wisedopas N., Ratanachu-Ek T., Kishida T., Moriyama M., Yamaoka Y., Mahachai V. <i>Helicobacter pylori</i> Infection in Thailand: A Nationwide Study of the CagA Phenotype. PLoS One, 2015, vol.10, no.9, e0136775.		DOI: 10.1371/journal.pone.0136775
16	Mukhopadhyay A.K., Kersulyte D., Jeong J.Y., Datta S., Ito Y., Chowdhury A., Santra A., Bhattacharya S.K., Azuma T., Nair G.B., Berg D.E. Distinctiveness of		DOI: 10.1128/jb.182.11.3219-3227.2000

	genotypes of <i>Helicobacter pylori</i> in Calcutta, India. <i>J. Bacteriol.</i> , 2000, vol.182, no.11, pp.3219-27.		
17	Rahman M., Mukhopadhyay A.K., Nahar S., Datta S., Ahmad M.M., Sarker S., Masud I.M., Engstrand L., Albert M.J., Nair G.B., Berg D.E. DNA-level characterization of <i>Helicobacter pylori</i> strains from patients with overt disease and with benign infections in Bangladesh. <i>J. Clin. Microbiol.</i> , 2003, vol.41, no.5, pp.2008-14.		DOI: 10.1128/jcm.41.5.2008-2014.2003
18	Tanih N.F., McMillan M., Naidoo N., Ndip L.M., Weaver L.T., Ndip R.N. Prevalence of <i>Helicobacter pylori</i> <i>vacA</i> , <i>cagA</i> and <i>iceA</i> genotypes in South African patients with upper gastrointestinal diseases. <i>Acta Trop.</i> , 2010, vol.116, no.1, pp.68-73.		DOI: 10.1016/j.actatropica.2010.05.011
19	Miehlke S., Kirsch C., Agha-Amiri K., Günther T., Lehn N., Malfertheiner P., Stolte M., Ehninger G., Bayerdörffer E. The <i>Helicobacter</i>		PMID: 10897035

	pylori vacA s1, m1 genotype and cagA is associated with gastric carcinoma in Germany. <i>Int. J. Cancer</i> , 2000, vol.87, no.3, pp. 322-327.		
20	Chiarini A., Calà C., Bonura C., Gullo A., Giuliana G., Peralta S., D'Arpa F., Giammanco A. Prevalence of virulence-associated genotypes of <i>Helicobacter pylori</i> and correlation with severity of gastric pathology in patients from western Sicily, Italy. <i>Eur. J. Clin. Microbiol. Infect. Dis.</i> , 2009, vol. 28, pp. 437–446.		DOI: 10.1007/s10096-008-0644-x
21	Heikkinen M., Mayo K., Mégraud F., Vornanen M., Marin S., Pikkarainen P., Julkunen R. Association of CagA-positive and CagA-negative <i>Helicobacter pylori</i> strains with patients' symptoms and gastritis in primary care patients with functional upper abdominal complaints. <i>Scand. J. Gastroenterol.</i> , 1998, vol.33, no.1, pp.31-38.		DOI: 10.1080/00365529850166176
22	Muhsen K., Sinnereich R., Beer-		DOI: 10.1017/S0950268819001456

	Davidson G., Nassar H., Abu Ahmed W., Cohen D., Kark J.D. Correlates of infection with <i>Helicobacter pylori</i> positive and negative cytotoxin-associated gene A phenotypes among Arab and Jewish residents of Jerusalem. <i>Epidemiol. Infect.</i> , 2019, vol.147, e276.		
23	Diab M., Shemis M., Gamal D., El-Shenawy A., El-Ghannam M., El-Sherbini E. <i>Helicobacter pylori</i> Western <i>cagA</i> genotype in Egyptian patients with upper gastrointestinal disease. <i>Egypt J. of Med. Human Gen.</i> , 2018, vol.19, no.4, pp.297-300.		https://doi.org/10.1016/j.ejmhg.2018.06.003
24	Schanova N.O., Prokhorova L.V. Improvement of <i>Helicobacter pylori</i> eradication efficacy at stomach and duodenum peptic ulcers. <i>Russian Journal of Gastroenterology, Hepatology, Coloproctology</i> , 2016, no.2, pp. 11-18.	Щанова Н.О., Прохорова Л.В. Возможности повышения эффективности эрадикации <i>Helicobacter pylori</i> у больных язвенной болезнью желудка и двенадцатиперстной кишки. Российский журнал гастроэнтерологии, гепатологии, колопроктологии №2, 2016 с. 11-18	eLIBRARY ID: 28923489

25	Sorokin V.M., Pisanov R.V., Vodop'janov A.S., Golubkina E.V., Bereznjak E.A. Comparative analysis of genotypes of <i>Helicobacter pylori</i> strains in the Rostov and Astrakhan regions. <i>Medical Herald of the South of Russia</i> , 2018, vol.9, no.4, pp.81-86	Сорокин В.М., Писанов Р.В., Водопьянов А.С., Голубкина Е.В., Березняк Е.А. Сравнительный анализ генотипов штаммов <i>Helicobacter pylori</i> в Ростовской и Астраханской области. <i>Медицинский вестник Юга России</i> Том 9, № 4 (2018) с. 81-86	DOI 10.21886/2219-8075-2018-9-4-81-86
26	Tsukanov V.V., Butorin N.N., Maady A.S., Shtygasheva O.V., Amelchugova O.S., Tonkikh J.L., Fassan M., Rugge M. <i>Helicobacter pylori</i> Infection, Intestinal Metaplasia, and Gastric Cancer Risk in Eastern Siberia. <i>Helicobacter</i> , 2011, vol.16, no. 2, pp.107-12.		DOI: 10.1111/j.1523-5378.2011.00827.x.
27	Akhtereeva A.R., Davidyuk Y.N., Faizullina R.A., et al. Prevalence of <i>Helicobacter pylori</i> genotypes in patients with gastroduodenal pathology in Kazan. <i>Kazan medical journal</i> , 2017, vol. 98, no.5, pp. 723-728.	Ахтереева А.Р., Давидюк Ю.Н., Файзуллина Р.А., Ивановская К.А., Сафин А.Г., Сафина Д.Д., Абдулхаков С.Р. Распространённость генотипов <i>Helicobacter pylori</i> у пациентов с гастродуоденальной патологией в Казани // <i>Казанский медицинский</i>	doi: 10.17750/КМЖ2017-723

		журнал. - 2017. - Т. 98. - №5. - С. 723-728.	
28	Van Doorn L.J., Figueiredo C., Mégraud F., Pena S., Midolo P., Queiroz D.M., Carneiro F., Vanderborcht B., Pegado M.D., Sanna R., De Boer W., Schneeberger P.M., Correa P., Ng E.K., Atherton J., Blaser M.J., Quint W.G. Geographic distribution of vacA allelic types of <i>Helicobacter pylori</i> . <i>Gastroenter.</i> , 1999, vol.116, no.4, :823-30.		DOI: 10.1016/s0016-5085(99)70065-x
29	Almeida N., Donato M.M., Romãozinho J.M., Luxo C., Cardoso O., Cipriano M.A., Marinho C., Fernandes A., Sofia C. Correlation of <i>Helicobacter pylori</i> genotypes with gastric histopathology in the central region of a South-European country. <i>Dig. Dis. Sci.</i> , 2015, vol.60, no.1, pp.74-85.		DOI: 10.1007/s10620-014-3319-8
30	Liu J., He C., Chen M., Wang Z., Xing C., Yuan Y. Association of presence/absence and on/off patterns		DOI: 10.1186/1471-2334-13-555

of <i>Helicobacter pylori</i> oipA gene with peptic ulcer disease and gastric cancer risks: a meta-analysis. BMC Infect. Dis., 2013, 13:555.		
--	--	--